WX [WuXi PharmaTech (Cayman)] 6-K: (Original Filing)
[WuXi PharmaTech (Cayman) Inc. Form 6-K Page 3 4 2 WuXi PharmaTech (Cayman) Inc. Edward Hu Chief Financial Officer 3]
WX [WuXi PharmaTech (Cayman)] 6-K: WuXi PharmaTech (Cayman) Inc. Form 6-K Page 3
[WuXi PharmaTech (Cayman) Inc. Form 6-K Page 3 4 2 WuXi PharmaTech (Cayman) Inc. Edward Hu Chief Financial Officer 3]
BSPM [Biostar Pharmaceuticals] S-8: Registration No. 333- FORM S-8 REGISTRATION STATEMENT UNDER
[Registration No. 333- FORM S-8 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Biostar Pharmaceuticals, Inc. Maryland (State or other jurisdiction of incorporation or organization) 20-5101287 (I.R.S. Employer Identification No.) No. 588 Shiji Xi Avenue, Xianyang, Shaanxi Province, People’s Republic of China 712046 Biostar Pharmaceuticals, Inc. 2013 Equity Incentive Plan (Full title of the plan) Ronghua Wang President and Chief] [BIOSTAR PHARMACEUTICALS, INC. 2013 EQUITY INCENTIVE PLAN, INC. ______________________ Section 1. Purpose. The purpose of the Biostar Pharmaceuticals, Inc. 2013 Equity Incentive Plan (the “Plan”) is to attract and retain outstanding individuals as Key Employees, Directors and Consultants of the Company and its Subsidiaries, to recognize the contributions made to the Company and its Subsidiaries by Key Employees, Directors and] [[Schiff Hardin LLP Letterhead] July 17, 2014 Biostar Pharmaceuticals, Inc. No. 588 Shiji Xi Avenue Xianyang, Shaanxi Province People’s Republic of China Ladies and Gentlemen: EX-5.1 3 ex5-1.htm EX-5.1] [CONSENT OF INDEPENDENT REGISTERED ACCOUNTING FIRM To the Board of Directors of Biostar Pharmaceuticals, Inc. We hereby consent to the incorporation by reference in the Registration Statement on Form S-8 dated July 17, 2014 of Biostar Pharmaceuticals, Inc. of our report dated March 31, 2014 relating to the consolidated financial statements, which appears in the Annual Report on Form 10-K]
SKBI [SKYSTAR BIO-PHARMACEUTICAL CO] SC 13G: (Original Filing)
[reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page. The information required in the remainder of this cover page shall not be deemed to be filed for the purpose of Section 18 of the Securities that]
SKBI [SKYSTAR BIO-PHARMACEUTICAL CO] SC 13G: reporting person’s initial filing on this form with
[reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page. The information required in the remainder of this cover page shall not be deemed to be filed for the purpose of Section 18 of the Securities that]
BSPM [Biostar Pharmaceuticals] S-8: (Original Filing)
[Registration No. 333- FORM S-8 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Biostar Pharmaceuticals, Inc. Maryland (State or other jurisdiction of incorporation or organization) 20-5101287 (I.R.S. Employer Identification No.) No. 588 Shiji Xi Avenue, Xianyang, Shaanxi Province, People’s Republic of China 712046 Biostar Pharmaceuticals, Inc. 2013 Equity Incentive Plan (Full title of the plan) Ronghua Wang President and Chief] [BIOSTAR PHARMACEUTICALS, INC. 2013 EQUITY INCENTIVE PLAN, INC. ______________________ Section 1. Purpose. The purpose of the Biostar Pharmaceuticals, Inc. 2013 Equity Incentive Plan (the “Plan”) is to attract and retain outstanding individuals as Key Employees, Directors and Consultants of the Company and its Subsidiaries, to recognize the contributions made to the Company and its Subsidiaries by Key Employees, Directors and] [[Schiff Hardin LLP Letterhead] July 17, 2014 Biostar Pharmaceuticals, Inc. No. 588 Shiji Xi Avenue Xianyang, Shaanxi Province People’s Republic of China Ladies and Gentlemen: EX-5.1 3 ex5-1.htm EX-5.1] [CONSENT OF INDEPENDENT REGISTERED ACCOUNTING FIRM To the Board of Directors of Biostar Pharmaceuticals, Inc. We hereby consent to the incorporation by reference in the Registration Statement on Form S-8 dated July 17, 2014 of Biostar Pharmaceuticals, Inc. of our report dated March 31, 2014 relating to the consolidated financial statements, which appears in the Annual Report on Form 10-K]
SVA [SINOVAC BIOTECH] 6-K: (Original Filing)
[Sinovac Announces Favorable Reduction in Value Added Tax Rate BEIJING, June 25, 2014 /PRNewswire/ -- Sinovac Biotech Ltd. (NASDAQ: SVA), a leading provider of biopharmaceutical products in China, today announced that the value added tax (or "VAT") rate applied to the sales of Sinovac's vaccine products will be reduced to 3% from the current rate of 6%, according to a] []
SKBI [SKYSTAR BIO-PHARMACEUTICAL CO] 8-K: (Original Filing)
[July 14, 2014 STRICTLY CONFIDENTIAL Weibing Lu Chairman of the Board Skystar Bio-Pharmaceutical Company 4/F Building B, Chuangye Square, No. 48 Keji Road Gaoxin District, Xi’an Province, P.R. China Dear Chairman Lu: Agreement Company Wainwright Offering Securities This letter agreement (this “ Compensation; Reimbursement Closing A. Cash Fee 1. 2. 430 Park Avenue | New York, New York 10022 |] [skystar bio-pharmaceutical company Holder Initial Exercise Date Termination Date Company Section 1 Definitions Purchase Agreement Section 2 Exercise 1 Exercise Price $6.25 Exercise Price b) Cashless Exercise c) VWAP “ 2 Mechanics of Exercise d) DWAC i. ii. Rescission Rights iii. 3 Buy-In iv. No Fractional Shares or Scrip v. 4 Charges, Taxes and Expenses provided however vi. Closing of] [July 16, 2014 Skystar Bio-Pharmaceutical Company 4/F, Building B, Chuangye Square, No. 48 Keji Rd Gaoxin District, Xi’an, Shaanxi Province, P.R. China Ladies and Gentlemen: Skystar Bio-Pharmaceutical Company In connection with the issuance by In connection with this opinion letter, we have examined and relied upon copies of the following documents, together with such other documents as we deemed necessary] [SECURITIES PURCHASE AGREEMENT Agreement Company Purchaser Purchasers This Securities Purchase Agreement (this “ Securities Act NOW, THEREFORE, IN CONSIDERATION of the mutual covenants contained in this Agreement, and for other good and valuable consideration the receipt and adequacy of which are hereby acknowledged, the Company and each Purchaser agree as follows: ARTICLE I. Definitions 1.1 Acquiring Person “ Action “] []
SVA [SINOVAC BIOTECH] 6-K: Sinovac Announces Favorable Reduction in Value Added Tax
[Sinovac Announces Favorable Reduction in Value Added Tax Rate BEIJING, June 25, 2014 /PRNewswire/ -- Sinovac Biotech Ltd. (NASDAQ: SVA), a leading provider of biopharmaceutical products in China, today announced that the value added tax (or "VAT") rate applied to the sales of Sinovac's vaccine products will be reduced to 3% from the current rate of 6%, according to a] []
